Abstract
DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Current Molecular Medicine
Title: Dendritic Cells and their Receptors in Antitumor Immune Response
Volume: 9 Issue: 6
Author(s): Raghvendra M. Srivastava and Ashok Khar
Affiliation:
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Abstract: DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Srivastava M. Raghvendra and Khar Ashok, Dendritic Cells and their Receptors in Antitumor Immune Response, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970715
DOI https://dx.doi.org/10.2174/156652409788970715 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Anticancer Effects of the Organosilicon Multidrug Resistance Modulator SILA 421
Anti-Cancer Agents in Medicinal Chemistry Do Epigenetic Marks Govern Bone Mass and Homeostasis?
Current Genomics Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design PP2A and Alzheimer Disease
Current Alzheimer Research Substance Abuse, HIV-1 and Hepatitis
Current HIV Research Pro-Oxidative Action of Polyphenols as Action Mechanism for their Pro-Apoptotic Activity
Anti-Cancer Agents in Medicinal Chemistry On the Search for Skin Gene Therapy Strategies of Xeroderma Pigmentosum Disease
Current Gene Therapy The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Current Protein & Peptide Science The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Managing Expectations in the Transition to Proof of Concept Studies
Reviews on Recent Clinical Trials Differential Splicing, Disease and Drug Targets
Infectious Disorders - Drug Targets Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Design, Synthesis, and Docking Studies of 4H-Chromene and Chromene Based Azo Chromophores: A Novel Series of Potent Antimicrobial and Anticancer Agents
Current Organic Synthesis RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy